Evidence map›Paper›PMID 29093272›Full record

ArticleJCI insight2017

T cells presenting viral antigens or autoantigens induce cytotoxic T cell anergy.

Nathalie E Blachère, Dana E Orange, Emily C Gantman, Bianca D Santomasso, Graeme C Couture, Teresa Ramirez-Montagut, John Fak, Kevin J O'Donovan, Zhong Ru, Salina Parveen and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCI insight, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Noninvasive Immuno-PET Imaging of CD8Frontiers in immunology · 2021
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Nathalie E BlachèreLaboratory of Molecular Neuro-Oncology, The Rockefeller University, New York, New York, USA.
Dana E OrangeLaboratory of Molecular Neuro-Oncology, The Rockefeller University, New York, New York, USA.
Emily C GantmanLaboratory of Molecular Neuro-Oncology, The Rockefeller University, New York, New York, USA.
Bianca D SantomassoLaboratory of Molecular Neuro-Oncology, The Rockefeller University, New York, New York, USA.
Graeme C CoutureLaboratory of Molecular Neuro-Oncology, The Rockefeller University, New York, New York, USA.
Teresa Ramirez-MontagutLaboratory of Molecular Neuro-Oncology, The Rockefeller University, New York, New York, USA.
John FakLaboratory of Molecular Neuro-Oncology, The Rockefeller University, New York, New York, USA.
Kevin J O'DonovanLaboratory of Molecular Neuro-Oncology, The Rockefeller University, New York, New York, USA.
Zhong RuLaboratory of Molecular Neuro-Oncology, The Rockefeller University, New York, New York, USA.
Salina ParveenLaboratory of Molecular Neuro-Oncology, The Rockefeller University, New York, New York, USA.
Mayu O FrankLaboratory of Molecular Neuro-Oncology, The Rockefeller University, New York, New York, USA.
Michael J MooreLaboratory of Molecular Neuro-Oncology, The Rockefeller University, New York, New York, USA.
Robert B DarnellLaboratory of Molecular Neuro-Oncology, The Rockefeller University, New York, New York, USA.
Rockefeller University · USHoward Hughes Medical Institute · USNew York Genome Center · USRegeneron (United States) · US

Funding

Transforming Translational Science and Education to Benefit Human HealthUL1TR000043 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY · 2012 to 2015
$26.8M
NEUROLOGY AND THE MOLECULAR ROLE OF N-RBPS IN THE BRAINR01NS034389 · NINDS · ROCKEFELLER UNIVERSITY · PI DARNELL, ROBERT B · 1995 to 2016
$6.3M
NCATS NIH HHS UL1 TR000043NINDS NIH HHS R01 NS034389
6 · The paper itself

Abstract

In the course of modeling the naturally occurring tumor immunity seen in patients with paraneoplastic cerebellar degeneration (PCD), we discovered an unexpectedly high threshold for breaking CD8+ cytotoxic T cell (CTL) tolerance to the PCD autoantigen, CDR2. While CDR2 expression was previously found to be strictly restricted to immune-privileged cells (cerebellum, testes, and tumors), unexpectedly we have found that T cells also express CDR2. This expression underlies inhibition of CTL activation; CTLs that respond to epithelial cells expressing CDR2 fail to respond to T cells expressing CDR2. This was a general phenomenon, as T cells presenting influenza (flu) antigen also fail to activate otherwise potent flu-specific CTLs either in vitro or in vivo. Moreover, transfer of flu peptide-pulsed T cells into flu-infected mice inhibits endogenous flu-specific CTLs. Our finding that T cells serve as a site of immune privilege, inhibiting effector CTL function, uncovers an autorepressive loop with general biologic and clinical relevance.

Indexed as

AnimalsAntigens, ViralAutoantigensAutoimmune DiseasesEpithelial CellsHeLa CellsHumansImmunizationInfluenza A virusMiceMice, Inbred C57BLMice, KnockoutNerve Tissue ProteinsNervous System DiseasesParaneoplastic Cerebellar DegenerationT-Lymphocytes, CytotoxicAntigens, ViralAutoantigensCDR2 protein, humanNerve Tissue Proteins

Identifiers

PMID29093272
PMCPMC5752293
OpenAlexW2765099619

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.